Dr. Leonardo Forero, MD
Medical Oncology (Medical Oncology Physician)
1000 S Coulter St, Suite 100
Amarillo, TX 79106
Who else practices at this address →
Potter County includes primary care (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 634
Licensed in Texas since 2004, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license M0076 (first issued 2004; active) -
Hematology & Oncology Physician
TX license M0076 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 634
- Services billed
- 228,411
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 48,000 | 52 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 26,520 | 33 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 23,520 | 25 |
| Injection, paclitaxel, 1 mg | 14,890 | 30 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 14,700 | 15 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12,801 | 112 |
| Injection, oxaliplatin, 0.5 mg | 12,423 | 13 |
| Injection, pembrolizumab, 1 mg | 11,700 | 23 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 10,150 | 30 |
| Injection, denosumab, 1 mg | 7,440 | 78 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Amarillo, TX | 44 |
| Prednisone Other prescribers in Amarillo, TX | 27 |
| Xtandi (enzalutamide) | 21 |
| Erivedge (vismodegib) | 18 |
| Anastrozole Other prescribers in Amarillo, TX | 16 |
| Tamoxifen Citrate Other prescribers in Amarillo, TX | 13 |
| Prochlorperazine Maleate Other prescribers in Amarillo, TX | 13 |
| Ondansetron Hcl Other prescribers in Amarillo, TX | 13 |
| Abiraterone Acetate | 12 |
| Tagrisso (osimertinib mesylate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $94.39 in total to this clinician.
| Exelixis Inc. | $45.39 |
|---|---|
| AbbVie Inc. | $28.89 |
| Novartis Pharmaceuticals Corporation | $20.11 |
| Food and Beverage | $94.39 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $156,390 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo Inc. · Recruiting · NCT06330064 - A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Jazz Pharmaceuticals Inc. - Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT01838512 - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc. - Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Daiichi Sankyo Inc. · Active, not recruiting · NCT05280470
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.